Drug Trial News

RSS
Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

New drug combination shows promise in patients with metastatic melanoma

New drug combination shows promise in patients with metastatic melanoma

Some lung cancer patients can benefit from melanoma drugs

Some lung cancer patients can benefit from melanoma drugs

RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

Wilson Therapeutics' WTX101-201 Phase 2 clinical study to be presented at EASL annual meeting

Wilson Therapeutics' WTX101-201 Phase 2 clinical study to be presented at EASL annual meeting

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

NIH-supported clinical trial to test statin use in patients with HIV-related cardiovascular disease

NIH-supported clinical trial to test statin use in patients with HIV-related cardiovascular disease

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

STRIVE study to assess safety, efficacy of rVSV-ZEBOV candidate Ebola vaccine

STRIVE study to assess safety, efficacy of rVSV-ZEBOV candidate Ebola vaccine

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Humabs BioMed reports clinical milestone in medImmune partnership

Humabs BioMed reports clinical milestone in medImmune partnership

MorphoSys to receive milestone payment for guselkumab program in psoriatic arthritis

MorphoSys to receive milestone payment for guselkumab program in psoriatic arthritis

Women in science: an interview with Professor Dame Carol Robinson, University of Oxford

Women in science: an interview with Professor Dame Carol Robinson, University of Oxford

Aeterna Zentaris plans to conduct Macrilen Phase 3 clinical study for AGHD

Aeterna Zentaris plans to conduct Macrilen Phase 3 clinical study for AGHD

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.